AND PROCEDURES.
−Removed: Management’s
Annual Report on Internal Control over Financial Reporting
−Removed: management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule
−Removed: 13a-15(f) and 15d-15(f) under the Exchange Act).
−Removed: Our internal control over financial reporting is a process designed to provide
−Removed: reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external
−Removed: purposes in accordance with GAAP.
+Added: management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f)
+Added: and 15d-15(f) under the Exchange Act).
+Added: Our internal control over financial reporting is a process designed to provide reasonable assurance
+Added: regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance
Our internal control over financial reporting includes those policies and procedures that:
−Removed: pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions
−Removed: of our assets;
−Removed: (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
−Removed: statements in accordance with GAAP, and that receipts and expenditures by us are being made only in accordance with authorizations
−Removed: of our management and directors;
−Removed: and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized
−Removed: acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.
−Removed: the supervision and with the participation of our management, including our principal executive officer and principal financial
−Removed: officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of the period covered
−Removed: by this report based on the criteria for effective internal control described in Internal Control –
−Removed: Integrated Framework
−Removed: (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).
−Removed: Based on the results
−Removed: of management’s assessment and evaluation, our management concluded that our internal control over financial reporting was
−Removed: effective as of December 31, 2020.
+Added: (i) pertain to the maintenance
+Added: of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
+Added: (ii) provide reasonable
+Added: assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that
+Added: receipts and expenditures by us are being made only in accordance with authorizations of our management and directors;
+Added: and (iii) provide
+Added: reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could
+Added: have a material effect on the consolidated financial statements.
+Added: the supervision and with the participation of our management, including our principal executive officer and principal financial officer,
+Added: we conducted an evaluation of the effectiveness of our internal control over financial reporting as of the period covered by this report
+Added: based on the criteria for effective internal control described in Internal Control – Integrated Framework (2013) issued by the
+Added: Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).
+Added: Based on the results of management’s assessment
+Added: and evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2021.
of Disclosure Controls and Procedures
1 unchanged sentence
of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
−Removed: Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the end of
−Removed: the period covered in this report, our disclosure controls and procedures were effective to provide reasonable assurance that
−Removed: the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed,
−Removed: summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our
−Removed: management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions
−Removed: regarding required disclosure.
+Added: Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period
+Added: covered in this report, our disclosure controls and procedures were effective to provide reasonable assurance that the information required
+Added: to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within
+Added: the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our principal executive
+Added: officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Limitations on Effectiveness of Controls
−Removed: assuming the effectiveness of our controls and procedures, our management, including our principal executive officer and principal
−Removed: financial officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent
−Removed: or detect all error or all fraud.
−Removed: A control system, no matter how well designed and operated, can provide only reasonable, not
−Removed: absolute, assurance that the control system’s objectives will be met.
−Removed: In general, our controls and procedures are designed
−Removed: to provide reasonable assurance that our control system’s objective will be met, and our principal executive officer and
−Removed: principal financial officer has concluded that our disclosure controls and procedures are effective at the reasonable assurance
−Removed: The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls
−Removed: must be considered relative to their costs.
−Removed: Further, because of the inherent limitations in all control systems, no evaluation
−Removed: of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues
−Removed: and instances of fraud, if any, within the Company have been detected.
−Removed: These inherent limitations include the realities that judgments
−Removed: in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.
−Removed: Controls can also be circumvented
−Removed: by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.
−Removed: of any system of controls is based in part on certain assumptions about the likelihood of future events and there can be no assurance
−Removed: that any design will succeed in achieving its stated goals under all potential future conditions.
−Removed: Projections of any evaluation
−Removed: of the effectiveness of controls in future periods are subject to risks.
−Removed: Over time, controls may become inadequate because of
−Removed: changes in conditions or deterioration in the degree of compliance with policies or procedures.
+Added: assuming the effectiveness of our controls and procedures, our management, including our principal executive officer and principal financial
+Added: officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error
+Added: or all fraud.
+Added: A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the
+Added: control system’s objectives will be met.
+Added: In general, our controls and procedures are designed to provide reasonable assurance that
+Added: our control system’s objective will be met, and our principal executive officer and principal financial officer has concluded that
+Added: our disclosure controls and procedures are effective at the reasonable assurance level.
+Added: The design of a control system must reflect the
+Added: fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.
+Added: Further, because of
+Added: the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error
+Added: or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.
+Added: These inherent
+Added: limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error
+Added: Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management
+Added: override of the controls.
+Added: The design of any system of controls is based in part on certain assumptions about the likelihood of future
+Added: events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
+Added: Projections of any evaluation of the effectiveness of controls in future periods are subject to risks.
+Added: Over time, controls may become
+Added: inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
in Internal Control Over Financial Reporting
−Removed: has been no change in our internal control over financial reporting that occurred during the fourth quarter of 2020 that
−Removed: has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
+Added: has been no change in our internal control over financial reporting that occurred during the fourth quarter of 2021 that has materially
+Added: affected, or is reasonably likely to materially affect, our internal control over financial reporting.
+Added: DISCLOSURE REGARDING
+Added: FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.
+Added: Not Applicable.
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
−Removed: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2021 Annual
−Removed: Meeting of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
+Added: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2022 Annual Meeting
+Added: of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
COMPENSATION.
−Removed: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2021 Annual
−Removed: Meeting of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
+Added: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2022 Annual Meeting
+Added: of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
−Removed: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2021 Annual
−Removed: Meeting of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
+Added: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2022 Annual Meeting
+Added: of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
−Removed: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2021 Annual
−Removed: Meeting of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
+Added: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2022 Annual Meeting
+Added: of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
ACCOUNTANT FEES AND SERVICES.
−Removed: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2021 Annual
−Removed: Meeting of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
+Added: information called for by this item is incorporated herein by reference to the definitive Proxy Statement for our 2022 Annual Meeting
+Added: of Stockholders, which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act.
AND FINANCIAL STATEMENT SCHEDULES.
1 unchanged sentence
Statement Schedules
−Removed: Certificate of Incorporation of Provectus Biopharmaceuticals, Inc., as amended (incorporated by reference to Exhibit 3.1 of the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017).
−Removed: Certificate of Designation for the Company’s Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed with the SEC on August 25, 2016).
+Added: Certificate of Incorporation of Provectus Biopharmaceuticals, Inc., as amended (incorporated by reference to Exhibit 3.1 of the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017).
+Added: Certificate of Designation for the Company’s Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed with the SEC on August 25, 2016).
+Added: Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed with the SEC on June 24, 2021).
+Added: Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 of the Company’s current report on Form 8-K filed with the SEC on June 24, 2021).
Bylaws of Provectus Biopharmaceuticals, Inc.
−Removed: (incorporated by reference to Exhibit 3.4 of the Company’s annual report on Form 10-K filed with the SEC on March 13, 2014).
−Removed: Specimen certificate for the Common Stock, par value $0.001 per share, of the Company (incorporated by reference to Exhibit 4.1 of the Company’s annual report on Form 10-KSB filed with the SEC on April 15, 2003).
−Removed: Specimen certificate for the Common Stock, par value $0.001 per share, of the Company (incorporated by reference to Exhibit 4.1 to the Company’s registration statement on Form S-4, Commission File No.
+Added: (incorporated by reference to Exhibit 3.4 of the Company’s annual report on Form 10-K filed with the SEC on March 13, 2014).
+Added: Specimen certificate for the Common Stock, par value $0.001 per share, of the Company (incorporated by reference to Exhibit 4.1 of the Company’s annual report on Form 10-KSB filed with the SEC on April 15, 2003).
+Added: Specimen certificate for the Common Stock, par value $0.001 per share, of the Company (incorporated by reference to Exhibit 4.1 to the Company’s registration statement on Form S-4, Commission File No.
333-208816, filed with the SEC on December 31, 2015).
−Removed: Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company’s current report on Form 8-K filed with the SEC on August 25, 2016).
+Added: Form of Unsecured Convertible Promissory Note (incorporated by reference to Exhibit 4.1 of the Company’s current report on Form 8-K filed with the SEC on August 18, 2021).
Description of Securities.
Confidentiality, Inventions and Non-Competition Agreement dated as of November 26, 2002 between the Company and Timothy C.
−Removed: Scott (incorporated by reference to Exhibit 10.9 of the Company’s annual report on Form 10-KSB filed with the SEC on April 15, 2003).
+Added: Scott (incorporated by reference to Exhibit 10.9 of the Company’s annual report on Form 10-KSB filed with the SEC on April 15, 2003).
Confidentiality, Inventions and Non-Competition Agreement dated as of November 26, 2002, between the Company and Eric A.
−Removed: Wachter (incorporated by reference to Exhibit 10.10 of the Company’s annual report on Form 10-KSB filed with the SEC on April 15, 2003).
−Removed: Material Transfer Agreement dated as of July 31, 2003 between Schering-Plough Animal Health Corporation and the Company (incorporated by reference to Exhibit 10.15 of the Company’s quarterly report on Form 10-QSB filed with the SEC on August 14, 2003).
+Added: Wachter (incorporated by reference to Exhibit 10.10 of the Company’s annual report on Form 10-KSB filed with the SEC on April 15, 2003).
+Added: Material Transfer Agreement dated as of July 31, 2003 between Schering-Plough Animal Health Corporation and the Company (incorporated by reference to Exhibit 10.15 of the Company’s quarterly report on Form 10-QSB filed with the SEC on August 14, 2003).
Controlled Equity Offering SM Sales Agreement, dated April 30, 2014, by and between Provectus Biopharmaceuticals, Inc.
and Cantor Fitzgerald & Co.
−Removed: (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on April 30, 2014).
+Added: (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on April 30, 2014) .
Stipulated Settlement Agreement and Mutual Release, dated June 6, 2014, by and among the Company as nominal defendant, H.
5 unchanged sentences
Smith, IV, as defendants, and Glenn Kleba and Don B.
−Removed: Dale, as plaintiffs (Exhibits Omitted) (incorporated by reference to Exhibit 10.6 of the Company’s quarterly report on Form 10-Q filed with the SEC on August 7, 2014).
−Removed: Form of Securities Purchase Agreement between Provectus Biopharmaceuticals, Inc.
−Removed: and the purchasers named therein (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on August 25, 2016) (exhibits and schedules have been omitted, and the Company agrees to furnish to the Commission a copy of any omitted exhibits and schedules upon request).
−Removed: Warrant Agency Agreement, dated August 30, 2016, by and between Provectus Biopharmaceuticals, Inc.
−Removed: and Broadridge Corporate Issuer Solutions, Inc.
−Removed: (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on August 30, 2016).
−Removed: Convertible Promissory Note dated February 21, 2017 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on February 21, 2017).
−Removed: Definitive Financing Commitment Term Sheet dated March 19, 2017 (incorporated by reference to Exhibit 10.2 of the Company’s quarterly report on Form 10-Q filed with the SEC on May 10, 2017).
−Removed: Secured Convertible Promissory Note between the Company and Cal Enterprises LLC, dated April 3, 2017 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on April 4, 2017).
−Removed: First Amendment to Amended and Restated Secured Convertible Promissory Note between the Company and CAL Enterprises LLC, dated January 22, 2018 (incorporated by reference to Exhibit 10.4 of the Company’s quarterly report on Form 10-Q filed with the SEC on May 9, 2018).
−Removed: Amended and Restated Secured Convertible Promissory Note between the Company and Eric A.
−Removed: Wachter, dated April 3, 2017 (incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed with the SEC on April 4, 2017).
−Removed: Second Amendment to Amended and Restated Secured Convertible Promissory Note between the Company and Eric Wachter, Ph.D., dated January 22, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s quarterly report on Form 10-Q filed with the SEC on May 9, 2018).
−Removed: Third Amendment to Amended and Restated Secured Convertible Promissory Note between the Company and Eric Wachter, Ph.D., dated January 22, 2018 (incorporated by reference to Exhibit 10.2 of the Company’s quarterly report on Form 10-Q filed with the SEC on May 9, 2018).
−Removed: Fourth Amendment to Amended and Restated Secured Convertible Promissory Note between the Company and Eric Wachter, Ph.D., dated January 22, 2018 (incorporated by reference to Exhibit 10.3 of the Company’s quarterly report on Form 10-Q filed with the SEC on May 9, 2018).
−Removed: Secured Convertible Promissory Note between the Company and Eric A.
−Removed: Wachter, dated January 25, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on January 30, 2018).
−Removed: Secured Convertible Promissory Note between the Company and Timothy C.
−Removed: Scott, dated February 23, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on February 26, 2018).
−Removed: Secured Convertible Promissory Note between the Company and Edward V.
−Removed: Pershing, dated July 26, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on July 30, 2018).
−Removed: 2020 Definitive Financing Term Sheet (incorporated by reference to Exhibit 10.39 to the Company’s annual report on Form 10-K filed with the SEC on March 5, 2020).
−Removed: Form of PRH 2 Secured Convertible Promissory Note (incorporated by reference to Exhibit 4.1 of the Company’s current report on Form 8-K filed January 7, 2020).
+Added: Dale, as plaintiffs (Exhibits Omitted) (incorporated by reference to Exhibit 10.6 of the Company’s quarterly report on Form 10-Q filed with the SEC on August 7, 2014).
+Added: Definitive Financing Commitment Term Sheet dated March 19, 2017 (incorporated by reference to Exhibit 10.2 of the Company’s quarterly report on Form 10-Q filed with the SEC on May 10, 2017).
+Added: 2020 Definitive Financing Term Sheet (incorporated by reference to Exhibit 10.39 to the Company’s annual report on Form 10-K filed with the SEC on March 5, 2020).
+Added: 2021 Financing Term Sheet (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q filed with the SEC on November 10, 2021).
Provectus Pharmaceuticals, Inc.
−Removed: 2012 Stock Plan (incorporated herein by reference to Appendix A of the Company’s definitive proxy statement filed with the SEC on April 30, 2012).
+Added: 2012 Stock Plan (incorporated herein by reference to Appendix A of the Company’s definitive proxy statement filed with the SEC on April 30, 2012).
2017 Amendment and Restatement of the Provectus Biopharmaceuticals, Inc.
−Removed: 2014 Equity Compensation Plan (incorporated herein by reference to Appendix A of the Company’s definitive proxy statement filed with the SEC on April 27, 2017).
−Removed: Independent Contractor Agreement, dated April 19, 2017, between the Company and Bruce Horowitz (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on April 20, 2017).
+Added: 2014 Equity Compensation Plan (incorporated herein by reference to Appendix A of the Company’s definitive proxy statement filed with the SEC on April 27, 2017).
+Added: Independent Contractor Agreement, dated April 19, 2017, between the Company and Bruce Horowitz (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed with the SEC on April 20, 2017).
Amendment No.
−Removed: 1 to the Independent Contractor Agreement, dated May 9, 2017, between the Company and Bruce Horowitz (incorporated by reference to Exhibit 10.6 of the Company’s quarterly report on Form 10-Q filed with the SEC on August 9, 2017).
+Added: 1 to the Independent Contractor Agreement, dated May 9, 2017, between the Company and Bruce Horowitz (incorporated by reference to Exhibit 10.6 of the Company’s quarterly report on Form 10-Q filed with the SEC on August 9, 2017).
Amendment No.
−Removed: 2 to the Independent Contractor Agreement dated April 19, 2017 between the Company and Bruce Horowitz, dated May 8, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed May 9, 2019).
−Removed: Employment Agreement between the Company and Heather Raines, CPA, dated March 25, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on March 25, 2019).
+Added: 2 to the Independent Contractor Agreement dated April 19, 2017 between the Company and Bruce Horowitz, dated May 8, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed May 9, 2019).
+Added: Employment Agreement between the Company and Heather Raines, CPA, dated March 25, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on March 25, 2019).
Executive Employment Agreement between the Company and Eric A.
−Removed: Wachter, Ph.D., dated May 17, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed May 20, 2019).
−Removed: Indemnification Agreement between the Company and Dominic Rodrigues, dated April 3, 2017 (incorporated by reference to Exhibit 10.3 of the Company’s current report on Form 8-K filed with the SEC on April 4, 2017).
−Removed: Indemnification Agreement between the Company and Bruce Horowitz, dated April 3, 2017 (incorporated by reference to Exhibit 10.4 of the Company’s current report on Form 8-K filed with the SEC on April 4, 2017).
−Removed: Indemnification Agreement between the Company and Ed Pershing, dated April 19, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on April 24, 2018).
−Removed: Indemnification Agreement between the Company and Jack Lacey, MD, dated April 19, 2018 (incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed on April 24, 2018).
−Removed: Indemnification Agreement between the Company and Webster Bailey, effective as of July 20, 2020 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on July 16, 2020).
−Removed: Code of Ethics (incorporated by reference to Exhibit 14 of the Company’s annual report on Form 10-K filed with the SEC on March 16, 2011).
−Removed: Subsidiaries of the Company (incorporated by reference to Exhibit 21 of the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017).
+Added: Wachter, Ph.D., dated May 17, 2019 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed May 20, 2019).
+Added: Indemnification Agreement between the Company and Dominic Rodrigues, dated April 3, 2017 (incorporated by reference to Exhibit 10.3 of the Company’s current report on Form 8-K filed with the SEC on April 4, 2017).
+Added: Indemnification Agreement between the Company and Bruce Horowitz, dated April 3, 2017 (incorporated by reference to Exhibit 10.4 of the Company’s current report on Form 8-K filed with the SEC on April 4, 2017).
+Added: Indemnification Agreement between the Company and Ed Pershing, dated April 19, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on April 24, 2018).
+Added: Indemnification Agreement between the Company and Jack Lacey, MD, dated April 19, 2018 (incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed on April 24, 2018).
+Added: Indemnification Agreement between the Company and Webster Bailey, effective as of July 20, 2020 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on July 16, 2020).
+Added: Code of Ethics (incorporated by reference to Exhibit 14 of the Company’s annual report on Form 10-K filed with the SEC on March 16, 2011).
+Added: Subsidiaries of the Company (incorporated by reference to Exhibit 21 of the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017).
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) of the Securities Exchange Act of 1934.
Certification of Principal Financial Officer pursuant to Rules 13a-14(a) of the Securities Exchange Act of 1934.
−Removed: 32††
Certification Pursuant to 18 U.S.C.
Section 1350.
−Removed: following financial information from Provectus Biopharmaceuticals, Inc.’s Annual Report on Form 10-K for the period
−Removed: ended December 31, 2020, filed with the SEC on March 2, 2021, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) the Consolidated Balance Sheet as of December 31, 2020 and 2019;
−Removed: (ii) the Consolidated Statements of Operations
−Removed: for the years ended December 31, 2020 and 2019;
−Removed: (iii) the Consolidated Statements of Equity for the years ended December 31,
−Removed: 2020 and 2019;
−Removed: (iv) the Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019;
−Removed: and (v) Notes
−Removed: to Consolidated Financial Statements.
−Removed: Filed herewith.
−Removed: ††
−Removed: Furnished herewith.
−Removed: Indicates a management
−Removed: contract or compensatory plan or arrangement.
−Removed: FORM 10-K SUMMARY.
−Removed: to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
−Removed: to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded
+Added: within the Inline XBRL document.
+Added: XBRL Taxonomy Extension Schema Document.
+Added: XBRL Taxonomy Extension Calculation Linkbase Document.
+Added: XBRL Taxonomy Extension Label Linkbase Document.
+Added: XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: XBRL Taxonomy Extension Definition Linkbase Document.
+Added: Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
+Added: a management contract or compensatory plan or arrangement.
+Added: 10-K SUMMARY.
+Added: to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
+Added: on its behalf by the undersigned, thereunto duly authorized.
BIOPHARMACEUTICALS, INC.
1 unchanged sentence
Operating Officer (principal executive officer)
−Removed: to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
−Removed: of the registrant and in the capacities and on the dates indicated.
+Added: to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
+Added: registrant and in the capacities and on the dates indicated.
Heather Raines
11 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.